Colitis F6: Colitis with anemia, red face, chronic low fever, anxiety, thirst, low WBC reading, easy bruising or uterine bleeding.
1. Colitis: 59 patients were divided into a treatment group (n=28) taking F6 and other herbal supplements while a comparison group taking regular medications (n=31). Cured: 5 vs. 1 (17.8 vs. 3.2 percent); improved: 23 vs. 17 (82.1 vs. 54.83 percent); not improved: 0 vs. 13 (0 vs. 41.9 percent). There is a significant difference between two groups, P<0.05.
2. Anemia: In many lab tests, F6 significantly improved RBC counts and overall health. Anemic mice were given the F6 formula at 18g/kg/d for 10 days and compared with a contrast group. The RBC reading was 4,200,000 versus 5,490.000; RBC in the treatment group was 30% higher than in the comparison group. Hemoglobin is 12.2 versus 16.0, also 30% higher. 50 patients who had suffered chronic uterine bleeding for 18 to 45 years, took F6 formula or its modifications. 42 were (84%) cured with no abnormal bleeding for one year, 6 improved (12%) with no recurrence in three months and 2 did not improve. Another 42 patients were treated with F6, and 31 were cured (73.81%), 7 improved (22.58%) and 4 did not improve (12.90%). Of 12 patients with uterine fibromylogia taking F6 with other formulas. 6 were cured, 5 improved and one did not improve.
3. Immune system: F6 shows great effects in improving immune function in both humans and lab animals. Among 21 cancer patients taking F6 for 15 days, all reported WBC and T-cells counts up significantly, p<0.05. 40 unknown-cause low WBC patients were divided evenly into a treatment group taking F6 and a comparison group taking regular western medicine. The results are: significantly improved: 8 vs. 1 (40% vs. 5%), improved: 11 vs. 10 (55% vs. 50%) and 1 vs. 9 (5% vs. 45%) did not improve after treatment. Another 15 low WBC count patients taking F6 or its modification had similar results. 30 cancer patients taking chemo therapy were divided evenly into three groups. The 10 patients in the F6 group all completed the whole chemo-therapy program with the least bone marrow damage. Purpura: F3 can significantly reduce the coagulation effects of blood palettes in animal tests, p<0.001. Of 24 purpura patients taking F6 for an average of two months, 7 were cured (29.16%), 12 significantly improved (50%) and the remaining 5 also improved (20.83%).
4. Gastritis: 59 ulcer gastritis patients were divided into a treatment group (n=31) using F6 and a comparison group (n=28) taking regular medicine. Cured: 5 vs. 1 (16% vs. 3.6%), improved: 23 vs. 17 (74% vs. 60.7%). There is a significant difference between the two groups, p<0.05..
Toxicity and side effects: There are no reported side effects or toxicity of F6. A very safe formula.
